During 2020, we collaborated with many of our customers to develop targeted liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) methods to detect SARS-CoV-2 (the virus that causes COVID-19) from biological samples. However, the combination of the biological… Read more >
Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing… Read more >
As scientific advances continue to carry researchers into new arenas, it is vital that technology evolves in tandem. At Waters, we understand that it is only by leveraging fit-for-purpose technologies that researchers are able to… Read more >
In this series, we review considerations for keeping your lab at the forefront of science. As you adjust to living and working in a pandemic and anticipate future global and geopolitical events, Waters remains dedicated… Read more >
Many years ago, I was hired by a biopharma company to develop analytical methods for therapeutic oligonucleotides. When a new colleague warned me about sample loss on LC columns I looked at him with skepticism.… Read more >
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while… Read more >
After completing my undergraduate degree, I began work at the New England Newborn Screening Program (NENBS) in Jamaica Plain, Massachusetts. It wasn’t long before I realized the magnitude of the job I held in serving… Read more >
What does “intelligence” mean in the context of biopharma analysis? Given the complex setting, much of the answer comes down to the task a user needs to complete, along with the question of who exactly… Read more >
Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of… Read more >
We’ve updated our UPLC systems to enable you to find faster, simpler, and better ways to do your work. Take a closer look at our new and improved ACQUITY UPLC PLUS Series.
